Participant-Reported Symptoms and Their Effect on Long-Term Adherence in the International Breast Cancer Intervention Study I (IBIS I)

Smith, Samuel G.; Šestak, Ivana; Howell, Anthony; Forbes, John F.; Cuzick, Jack

doi:10.1200/jco.2016.71.7439

Cited by 43 publications

(42 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A prompt symptom management and safety reassurance by the physician helped women to be motivated to adhere to the treatment. The recent analysis from the IBIS I study showed a higher drop-out rates in the tamoxifen arm, but the adherence did not differ between tamoxifen and placebo considering the overall reported symptoms (9). This leads to a further issue, i.e., the nocebo effect, that might be crucial in a preventive treatment.…”

Section: Discussionmentioning

confidence: 98%

See 1 more Smart Citation

Quality of Life in a Randomized Breast Cancer Prevention Trial of Low-Dose Tamoxifen and Fenretinide in Premenopausal Women

Serrano

Gandini

Guerrieri-Gonzaga

et al. 2018

Cancer Prevention Research

View full text Add to dashboard Cite

Menopausal symptoms are the main reason for withdrawal in tamoxifen prevention trials. Here, we present Menopause Quality of Life (MenQoL) assessment within a randomized 2 Â 2 phase II clinical trial of low-dose tamoxifen and the synthetic retinoid fenretinide. A total of 235 premenopausal women at higher risk for breast cancer were randomized to either tamoxifen 5 mg daily, fenretinide 200 mg daily, their combination, or placebo. Climacteric symptoms were investigated using the MenQoL questionnaire which was self-administered at each visit for 2 years of treatment and for 1 year of follow-up. CYP2D6 was genotyped in subjects taking tamoxifen to study the association with menopausal symptoms. The MenQoL effect size analysis showed no statistically significant difference among the four treatment arms for all four domains (vasomotor, physical, psychosocial, and sexual). Vasomotor symptoms only slightly increased under tamoxifen, with a score at year two of 1.45, 1.21, 0.58, and 1.17 in the combined, tamoxifen, fenretinide, and placebo arms, respectively. Compared with the slow metabolizers, a higher percentage of subjects with CYP2D6 extensive metabolizer genotype complained of a !3 score in the vasomotor, psychosocial, and sexual domain in the tamoxifen arms (P value ¼ 0.01, 0.007, and 0.007, respectively). QoL in premenopausal or perimenopausal women was not significantly worsened by low-dose tamoxifen or fenretinide. Our findings suggest that a low dose of tamoxifen may increase its acceptability for breast cancer prevention. Cancer Prev Res; 11(12); 811-8. Ó2018 AACR.

show abstract

Section: Discussionmentioning

confidence: 98%

“…Menopausal symptoms (hot flashes and night sweats) were a main reason for full-dose tamoxifen treatment withdrawal in the IBIS I trial (9). Maintaining a high QoL is therefore crucial to implement therapeutic prevention on a large scale.…”

Section: Introductionmentioning

confidence: 99%

Quality of Life in a Randomized Breast Cancer Prevention Trial of Low-Dose Tamoxifen and Fenretinide in Premenopausal Women

Serrano

Gandini

Guerrieri-Gonzaga

et al. 2018

Cancer Prevention Research

View full text Add to dashboard Cite

show abstract

“…Song and coworkers ( Song et al . 2001 ) reported that long-term estrogen deprivation leads to estrogen-induced apoptosis in LTED breast cancer cell population in vitro .…”

Section: Evolution Of Acquired Resistance In Prostate and Breast Cancmentioning

confidence: 99%

“…Laboratory studies of acquired resistance to antihormone therapies ( Wolf & Jordan 1993 , Yao et al . 2000 , Song et al . 2001 ) opened the door to understanding the ‘carry over’ effect of long-term adjuvant antiestrogen therapy that decreases mortality after adjuvant therapy is stopped ( Fisher et al .…”

Section: An Approach To Global Health Care Maintenance In Prostate Anmentioning

confidence: 99%

See 1 more Smart Citation

A unifying biology of sex steroid-induced apoptosis in prostate and breast cancers

Maximov¹,

Abderrahman²,

Curpăn³

et al. 2018

Endocrine-Related Cancer

View full text Add to dashboard Cite

Prostate and breast cancer are the two cancers with the highest incidence in men and women, respectively. Here we focus on the known biology of acquired resistance to antihormone therapy of prostate and breast cancer and compare laboratory and clinical similarities in the evolution of the disease. Laboratory studies and clinical observations in prostate and breast cancer demonstrate that cell selection pathways occur during acquired resistance to antihormonal therapy. Following sex steroid deprivation, both prostate and breast cancer models show an initial increased acquired sensitivity to the growth potential of sex steroids. Subsequently, prostate and breast cancer cells either become dependent upon the antihormone treatment or grow spontaneously in the absence of hormones. Paradoxically, the physiologic sex steroids now kill a proportion of selected, but vulnerable, resistant tumor cells. The sex steroid receptor complex triggers apoptosis. We draw parallels between acquired resistance in prostate and breast cancer to sex steroid deprivation. Clinical observations and patient trials confirm the veracity of the laboratory studies. We consider therapeutic strategies to increase response rates in clinical trials of metastatic disease that can subsequently be applied as a preemptive salvage adjuvant therapy. The goal of future advances is to enhance response rates and deploy a safe strategy earlier in the treatment plan to save lives. The introduction of a simple evidence based enhanced adjuvant therapy as a global healthcare strategy, has the potential to control recurrence, reduce hospitalization, reduce healthcare costs, and maintain a healthier population that contributes to society.

show abstract

Endocrine Therapy for Hormone Receptor‐Positive Breast Cancer

Buzdar

Dawood

Harvey

et al. 2019

Holland‐Frei Cancer Medicine

View full text Add to dashboard Cite

OverviewThe importance of the reproductive endocrine system in breast cancer treatment began to be appreciated at the turn of the nineteenth century. It was around this time that it was realized that approximately one‐third of premenopausal women with advanced breast cancer would respond to oophorectomy. However, it was only when the estrogen receptor (ER) was discovered that it was possible to fully appreciate the mechanisms underlying the activity of ovarian ablation and other associated treatments for breast cancer such as ovarian irradiation, adrenalectomy, and hypophysectomy. Research into both the estrogen and progesterone pathways not only provided a deeper understanding of the underlying mechanism of the carcinogenic pathway involved in the development of breast cancer but also allowed identification of potential targets for therapeutic intervention.This chapter discusses the recent advances in the molecular biology and physiology underlying the estrogen and progesterone receptor (PR) pathways and potential targets for intervention. In addition, it examines and compares the pharmacology and efficacy of the different endocrine agents used in the management of both early‐ and advanced‐stage breast cancer.

show abstract

Participant-Reported Symptoms and Their Effect on Long-Term Adherence in the International Breast Cancer Intervention Study I (IBIS I)

Cited by 43 publications

References 42 publications

Quality of Life in a Randomized Breast Cancer Prevention Trial of Low-Dose Tamoxifen and Fenretinide in Premenopausal Women

Quality of Life in a Randomized Breast Cancer Prevention Trial of Low-Dose Tamoxifen and Fenretinide in Premenopausal Women

A unifying biology of sex steroid-induced apoptosis in prostate and breast cancers

Endocrine Therapy for Hormone Receptor‐Positive Breast Cancer

Contact Info

Product

Resources

About